

Studie	Publiziert in	Kurzbeschreibung unter
9M-Best-Studie (Benefit and Efficacy in Severely Demented Patients during Treatment with Memantin)	[Int Geriatr Psychiatry 1999; 14 135–146]	Memantin, S. 448
4S-Studie Scandinavian Simvastatin Survival Study	[Lancet 1994; 244: 1383–1389], [Arch Intern Med 1996; 156: 2085–2092]	Simvastatin, S. 608
ABCD-Studie Appropriate Blood Pressure Control in Diabetes	[Engl J Med 1998; 338: 645–652]	Enalapril, S. 310
ACCESS-Studie Acute Candesartan Cilexetil Evaluation in Stroke Survivors	[still running study]	Candesartan, S. 205
ACCESS-Studie Atorvastatin Comparative Cholesterol Efficacy and Safety Study	[49th Annual Scientific Session of the American College of Cardiology Anaheim, March 2000]	Atorvastatin, S. 174 Fluvastatin, S. 351 Lovastatin, S. 436 Simvastatin, S. 608 Pravastatin, S. 561
ACCORD-Studie Angioplastie Coronaire, Corvasal and Diltiazem study	[Circulation 1997; 95: 83–89]	Diltiazem, S. 288
ACTION-Studie A Coronary disease Trial Investigation Outcome with Nifedipine GITS	[still running study]	Nifedipin, S. 498
ADOPT-Studie (A Diabetes outcome Progression Trial)	[N. Engl. J. Med. 355 (2006), 2427–2443]	Rosiglitazon, S. 594
AFCAPS/texCAPS-Studie The Air Force/Texas Coronary Atherosclerosis Prevention Study	[JAMA 1998; 279: 1615–1622], [Am J Cardiol 1997; 80: 287–293]	Lovastatin, S. 436
AIRE-Studie Acute Infarction Ramipril Efficacy study	[Eur Heart J 1997; 18: 41–51]	Ramipril, S. 581
AIREX-Studie AIRE extension study	[Lancet 1997; 349: 1493–1497]	Ramipril, S. 581
ALADIN III-Studie Alpha-Lipoic Acid in Diabetic Neuropathy-III-study	[Diabetes Care 1999; Vol 22: Issue 8, 1296–1301]	Liponsäure, S. 425
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial	[a-t 1999; Nr. 12: 127], [Script 2000; Nr. 2524: 22], [Lancet 2000; 355: 863–864], [JAMA 2002; 288: 2981–97]	Chlortalidon, S. 231
ARREST-Studie Amiodarone in the Out-of-Hospital Resuscitation of Refractory Sustained Ventricular Tachyarrhythmias	[P. Kudenchuk, 70. Tagung der American Heart Association, 1997, Orlando, USA]	Amiodaron, S. 160
ASCOT-LLA-Studie (Anglo-scandinavian cardiac outcomes trial lipid-lowering arm)	[Lancet 2003; 361: 1149–58]	Atorvastatin, S. 174
ASCOT-Studie Anglo-Scandinavian Cardiac Outcomes Trial	[Lancet 2003; 361: 1149–1158]	Atorvastatin, S. 174
ASSENT-3-Studie Assessment of the Safety and Efficacy of New Thrombolytic regimens 3	[Lancet 2001; 358: 605–613]	Tenecteplase, S. 626

Studie	Publiziert in	Kurzbeschreibung unter
ASTRONAUT-Studie Acid Suppression Trail: Ranitidin versus Omeprazole for NSAR-Associated Ulcer Treatment study	[N Engl J Med 1998; 338: 719]	Omeprazol, S. 512 Ranitidin, S. 582
ATLAS-Studie Assessment of Treatment with Lisinopril and Survival	[Circulation 1999; 100: 2312]	Lisinopril, S. 426
ATTRACT-Studie Anti-TNF Trial in Rheumatoid Arthritis with Concomitant Therapy	[Lancet 1999; Vol. 354: 1932–39]	Infliximab, S. 384
AVERT-Studie Atorvastatin Versus Revascularisation Treatment	[N Engl J Med 1999; 341: 70]	Atorvastatin, S. 174
AVID-Studie Antiarrhythmics Versus Implantable Defibrillators Study	[N Engl J Med 1997; 337: 1569]	Amiodaron, S. 160
AZACS-Studie Azithromycin in Acute Coronary Syndrom	[Lancet 2003; 361:809–813], [Deutsches Ärzteblatt 2003; Jg. 100, Heft 12: A-117]	Azithromycin, S. 178
BIP-Studie Bezafibrat Infarction Prevention Trial	[J Clin Epidemiol 1995; 48: 757–765], [Circulation 2000; 102: 21–27]	Bezafibrat, S. 185
Brustkrebs Präventionsstudie	[JAMA 2006; 295: 2727–41]	Raloxifen, S. 580
CADILLAC-Studie Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications	[Der Internist 2000; 41: 402–404]	Abciximab, S. 137
CALM-PD-Studie Comparison of the Agonist pramipexole with Levodopa on the Motorcomplications of Parkinson's Disease	[JAMA 2002; 287: 1653–1661]	Pramipexol, S. 560
CANDHY-Studie Candesartan in Hypertension	[International Forum on Angiotensin II Antagonism, Monte Carlo, 1999]	Candesartan, S. 205
CAPRIE-Studie Clopidogrel cersus Aspirin in Patiens at Risk of Ischämïc Events	[Lancet 1996; 348: 1929–1339]	Clopidogrel, S. 250
CAPRICORN-Studie Carvedilol Post-infarct survival controlled evaluation	[Eur J Heart Fail 2000; 2(3): 325–332], [Lancet 2001; 357: 1385–90]	Carvedilol, S. 212
CAPTURE-Studie Chimeric 7E3 Antiplatelet Therapy in Unstable angina Refractory to standard treatment	[Lancet 1997; 349: 1429–1435]	Abciximab, S. 137
CARE-Studie Cholesterol And Recurrent Events trial	[Am J Cardiol 1992; 68: 1436–1446]	Pravastatin, S. 561
CAST-Studie Collaborated Group Trial of early Aspirin use in 20000 patients with acute ischemic Stroke	[Lancet 1997; 349: 1641–1649]	Acetylsalicylsäure, S. 144
CHAMP-Studie Combination Hemotherapy And Mortality Prevention	[Der Internist 2000; 4: 402–404]	Acetylsalicylsäure, S. 144 Warfarin, S. 674

Studie	Publiziert in	Kurzbeschreibung unter
CHAMPS-Studie Controlled High Risk Subjects Avonex Multiple Sclerosis Prevention Study	[52nd Annual Meeting of the American Academy of Neurology, San Diego, May 2000]	Interferon β_{1a} , S. 392
CHARM-Studie Candesartan in Heart failure – Assessment of Reduction in Mortality	[still running study]	Candesartan, S. 205
CIBIS II-Studie Cardiac Insufficiency Bisoprolol Study II	[Lancet 1999; 353: 9–13], [Fund Clin Pharmacol 1997; 11: 138–142]	Bisoprolol, S. 187
CLASS-Studie Celecoxib Longterm Arthritis Safety Study	[JAMA 2000; 284: 1247–1255]	Celecoxib, S. 222
COMET-Studie Carvedilol Or Metoprolol European Trial	[Lancet 2003; 362 : 2–3 und 7–13]	Metoprolol, S. 466 Carvedilol, S. 212
CONSENSUS-Studie Cooperative North Scandinavian Enalapril Survival Study	[Eur Heart J 1999; 20: 136–139], [Am J Cardiol 1992; 69: 103–107]	Enalapril, S. 310
CONSENSUS II-Studie Cooperative North Scandinavian Enalapril Survival Study II	[N Eng J Med 1992; 327: 678–684]	Enalapril, S. 310
COPERNICUS-Studie Carvedilol Prospective Randomized Cumulative Survival Trial	[Packer M., 22. Kongress der Europäischen Gesellschaft für Kardiologie, Amsterdam, 29.10.2000], [N Engl J Med 2001; 344: 1651–8]	Carvedilol, S. 212
CRASH-Studie Corticosteroid Randomisation After Significant Head Injury	[Lancet 2004; 364: 1321–1328]	Methylprednisolon, S. 461
CREDO-Studie Clopidogrel for the Reduction of Events Observation	[Arzneimitteltherapie, 21. Jahrgang, Heft 3/2003: 88]	Clopidogrel, S. 250
CURE-Studie Clopidogrel in Unstable angina to prevent Recurrent ischemic Events	[Eur Heart J 2000; 21: 2033–41], [N Engl J Med 2001; 345: 494–502], [Lancet 2001; 358: 527–33]	Clopidogrel, S. 250
DAIS-Studie Diabetic Atherosclerosis Intervention Study	[Lancet 2001; 357: 905–10], [Diabetologia 1996; 39: 1655–61]	Fenofibrat, S. 330
DETAIL-Studie Diabetes exposed to Telmisartan and Enalapril	[ESC-Kongress 2004, München, 8/04; N Engl. J Med 2004; 351: 1952–61]	Enalapril, S. 310
DIG-Studie Digitalis Investigation Group	[Arzneimitteltherapie, 21. Jahrgang, Heft 4/2003: 122]	Digoxin, S. 282
DREAM-Studie (Diabetes reduction Assesment with Rampiril und Rosiglitazon Medication)	[Lancet 2006; 368: 1096–105]	Rosiglitazon, S. 594 Rampiril, S. 581
EAFST-Studie European Atrial Fibrillation Trial	[N Eng J Med 1995; 333: 5–10]	Acetylsalicylsäure, S. 144
Early-Studie	[European Society of Cardiology (ESC) in Wien Nov. 2007]	Bosentan, S. 189 Sildenafil, S. 607
ECASS II-Studie European Cooperative Acute Stroke Study	[JAMA 1995; 274: 1017–1025 und 1058–1059]	rt-PA, S. 597

Studie	Publiziert in	Kurzbeschreibung unter
ELITE I-Studie Evaluation of Losartan in the Elderly Study I	[Lancet 1997; 349: 747–752]	Losartan, S. 434
ELITE II-Studie Evaluation of Losartan in the Elderly Study II	[Der Internist 2000; 41: 402–404]	Losartan, S. 434
ELSA-Studie European Lacidipin Study on Atherosclerosis	[Circulation 2002; 106: 2422–2427]	Lacidipin, S. 409 Atenolol, S. 173
EPILOG-Studie Evaluation in PTCA to Improve Long-term Outcome with Abciximab GP IIb/IIIa Blockade	[N Engl J Med 1997; 336: 1698–1696]	Abciximab, S. 137
EPISTENT-Studie Evaluation of Platelete IIb/IIIa Inhibitor for Stenting	[Lancet 1999; 354: 2019–24], [N Engl J Med 1999; 341: 319–27]	Abciximab, S. 137
ESSENCE-Studie Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events	[N Engl J Med 1997; 337: 447–452], [Lancet 1998; 252: 87]	Enoxaparin, S. 313
ETAC-Studie Early Treatment of the Atopic Child	[J Allergy Clin Immunol 1999; 104: 433–40]	Cetirizin, S. 225
EVIDENCE-Studie Evidence for Interferon Dose-response: European-North American Comparative Efficacy	[ENS-Congress, 14–18th June 2003, Istanbul, Turkey]	Interferon β_{1a} , S. 392
EXCEL-Studie Expanded Clinical Evaluation of Lovastatin study	[Am J Med 1991; 91 (Suppl. 1B): 185–245]	Lovastatin, S. 436
FLIRT-Studie Fluvastatin Lipid lowering effect In Routine practice conditions Trial	[Clin Drug Invest 1997; 14: 146–153]	Fluvastatin, S. 351
FRISC II-Studie Fast Revascularization Instability in Coronary Artery Disease Study	[Lancet 1999; 354: 708–15]	Dalteparin, S. 266
GISSI I-III-Studie Gruppo Italiano per lo Studio della Streptochinasinell'Infarto miocardico	[Circulation 1996; 94: 432–436], [J Am Coll Cardiol 1996; 27: 337–344]	rt-PA, S. 597 Streptokinase, S. 614
GUSTO I-Studie Global Utilisation of Streptokinase and TPA for Occluded coronary arteries trial I	[J Am Coll Cardiol 1996; 28: 331–337], [Circulation 1996; 94: 1233–1238 und 1826–1833]	rt-PA, S. 597
GUSTO V-Studie Global Utilisation of Streptokinase and TPA for Occluded coronary	[Lancet 2001; 357:1905–14]	Abciximab, S. 137
HAEST-Studie Heparin in Acute Embolic Stroke Trial	[Lancet 2000; 355: 1205–10]	Dalteparin, S. 266
HART II-Studie Heparin and Aspirin Reperfusion Therapy II	[Circulation 2001; 104: 648–52]	Enoxaparin, S. 313
HERS-Studie Heart and Estrogen/Progestin Replacement Study	[Lancet 2000; 355: 1338], [Script 2000; Nr. 2530: 22]	Estradiol, S. 320